Literature DB >> 17162990

Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.

Yasunori Oka1, Yuichi Inoue, Takashi Kanbayashi, Kenji Kuroda, Masayuki Miyamoto, Tomoyuki Miyamoto, Akio Ikeda, Tetsuo Shimizu, Yasuo Hishikawa, Hiroshi Shibasaki.   

Abstract

STUDY
OBJECTIVES: Cerebrospinal fluid (CSF) hypocretin-1 levels and their relationship with the clinical characteristics of narcolepsy without cataplexy have not been well elucidated. Our aim was to examine whether clinical characteristics vary with CSF hypocretin-1 levels among narcoleptic patients without cataplexy.
DESIGN: Clinical features, variables on the multiple sleep latency test, and results of HLA typing were correlated with CSF hypocretin-1 levels.
SETTING: University-based sleep laboratories and a sleep disorders center. PATIENTS: Seventeen patients (5 male, 12 female) who fulfilled the diagnostic criteria of narcolepsy without cataplexy according to the International Classification of Sleep Disorders. INERVENTIONS: Patients underwent lumbar puncture for CSF sampling. MEASUREMENTS AND
RESULTS: Five patients showed a markedly decreased CSF hypocretin-1 level, whereas the remaining 12 patients showed almost normal levels. The mean rapid eye movement (REM) latency was significantly shorter and the age at onset was significantly earlier in the low CSF hypocretin-1 group compared with the normal CSF hypocretin-1 group. HLA-DR2 was positive in all of the patients with low CSF hypocretin-1, whereas only 33.3% of patients with normal CSF hypocretin-1 were DR2 positive.
CONCLUSIONS: Some narcoleptic patients without cataplexy have low CSF hypocretin-1 levels. In patients who have narcolepsy without cataplexy, short mean REM latency, younger age at onset, and HLA-DR2 are associated with CSF hypocretin-1 deficiency. Markedly decreased CSF hypocretin-1 levels could be a significant marker for identifying subgroups of narcolepsy patients without cataplexy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17162990     DOI: 10.1093/sleep/29.11.1439

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  8 in total

1.  Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.

Authors:  Stine Knudsen; Poul J Jennum; Jørgen Alving; Søren Paludan Sheikh; Steen Gammeltoft
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

2.  miRNA profiles in plasma from patients with sleep disorders reveal dysregulation of miRNAs in narcolepsy and other central hypersomnias.

Authors:  Anja Holm; Claus Heiner Bang-Berthelsen; Stine Knudsen; Birgitte R Kornum; Signe Modvig; Poul Jennum; Steen Gammeltoft
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

3.  CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.

Authors:  Takashi Kanbayashi; Tohru Kodama; Hideaki Kondo; Shinsuke Satoh; Yuichi Inoue; Shigeru Chiba; Tetsuo Shimizu; Seiji Nishino
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

4.  The impact of gender on timeliness of narcolepsy diagnosis.

Authors:  Christine Won; Mandana Mahmoudi; Li Qin; Taylor Purvis; Aditi Mathur; Vahid Mohsenin
Journal:  J Clin Sleep Med       Date:  2014-01-15       Impact factor: 4.062

5.  Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Authors:  Olivier Andlauer; Hyatt Moore; Seung-Chul Hong; Yves Dauvilliers; Takashi Kanbayashi; Seiji Nishino; Fang Han; Michael H Silber; Tom Rico; Mali Einen; Birgitte R Kornum; Poul Jennum; Stine Knudsen; Sona Nevsimalova; Francesca Poli; Giuseppe Plazzi; Emmanuel Mignot
Journal:  Sleep       Date:  2012-09-01       Impact factor: 5.849

6.  Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.

Authors:  Thomas C Thannickal; Robert Nienhuis; Jerome M Siegel
Journal:  Sleep       Date:  2009-08       Impact factor: 5.849

Review 7.  Hypersomnia and depressive symptoms: methodological and clinical aspects.

Authors:  Yves Dauvilliers; Régis Lopez; Maurice Ohayon; Sophie Bayard
Journal:  BMC Med       Date:  2013-03-21       Impact factor: 8.775

8.  Polysomnographic Assessment of Sleep Comorbidities in Drug-Naïve Narcolepsy-Spectrum Disorders--A Japanese Cross-Sectional Study.

Authors:  Taeko Sasai-Sakuma; Akihiko Kinoshita; Yuichi Inoue
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.